What is RPRX's current stock price?

As of now, RPRX is trading at $39.72, with a daily change of -1.22%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

RPRX Stock Analysis & IQ Rating | Royalty Pharma plc

RPRX

Royalty Pharma plc

$39.72

-$0.49 | -1.22%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$41.7

MKT CAP

$22.93B

52W Low

$29.66

VOL

$2.42M

P/E Ratio

22.72

AVG VOL

$4.09M

RSI

52.20

TREND

Uptrend

RPRX Stock IQ

Login to see Royalty Pharma plc (RPRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

RPRX Target Price

Login to display

Strengths

RPRX Rewards

Earnings are forecast to grow

RPRX Rewards

Pays a reliable dividend

RPRX Rewards

Upgraded on attractively valued

RPRX Price Performance

$38.31 (+3.68%)

$36.62 (+8.47%)

$36.32 (+9.36%)

$31.58 (+25.78%)

1year

6month

3month

1month

RPRX Risk Level

RPRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

RPRX Analysts Opinion

RPRX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

RPRX Analysts Opinion

RPRX Analysts opinion is negative and it remained unchanged from the past 3 months

RPRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

RPRX Street Sentiment

RPRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

RPRX Performance Sentiment

Sentiments overview associated with RPRX events and the stock performance.

84%

0%

Positive

Negative

16 out of 19
events present

0 out of 19
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$40.21

Resistance
Price

$38.31

Current Price Range

$41.39

Show methods +

Linked to RPRX

IQ

Close Price

Change

TEVA

4.43

32.35

-0.90%

Recently Viewed

Close Price

Change

RPRX

Royalty Pharma plc

39.72

-1.22%

HMY

Harmony Gold Mining

21.95

+1.25%

NIU

Niu Technologies

3.15

-3.67%

AQN

Algonquin Power &

6.44

+0.47%

ELME

Elme Communities

3.10

+3.68%

RPRX Latest Analysis +

Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.

Tue Jan 13, 2026

$40.36 | +0.21%

Activity

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug. Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate TEV-408 while keeping global commercial control.

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference. – Strong Sephience™. (sepiapterin) launch continues with unaudited Q4 global revenue of – Unaudited 2025 total product and royalty revenue of approximately – 2026 product revenue guidance of – Strong cash position of approximately ) today provided an update on the Company'.s progress and its outlook for 2026. ".2025 was a highly successful year for PTC highlighted by the initial regulatory approvals of Seph

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

Potential

Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment . (RTTNews) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals a United States affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) have announced a funding agreement of up to $500 million to advance the clinical development of Tevas anti-IL-15 antibody candidate TEV-408 for vit

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development . (RTTNews) - Royalty Pharma plc (RPRX) and Teva Pharmaceuticals a United States affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) have entered into a funding agreement of up to $500 million to accelerate the clinical development of Tevas anti-IL-15 antibody TEV-408. IL-15 is a ke

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

Royalty Pharma raises quarterly dividend by 6.8% to $0.235/share.

Fri Jan 9, 2026

$40.17 | -0.22%

Activity

Royalty Pharma Announces Dividend Increase. NEW YORK Jan. 09 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share reflecting a 6.8% increase in the companys quarterly dividend over the previous quarters dividend.

Fri Jan 9, 2026

$40.17 | -0.22%

Activity

Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics . (RTTNews) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics remaining royalty interest in Roches Evrysdi. The transaction includes an upfront payment of $240 million and up to $60 million in sales-based milestone payments.

Tue Dec 30, 2025

$38.99 | -0.23%

Activity

Royalty Pharma Acquires Remaining Royalty Interest in Roches Evrysdi for $240 Million and Potential Milestones. Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020

Mon Dec 29, 2025

$39.08 | -0.36%

Activity

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi.

Mon Dec 29, 2025

$39.08 | -0.36%

Activity

FAQ About RPRX Stock Insights

What is RPRX current stock price?

What are RPRX stock strengths?

What is RPRX Risk Level?

What is RPRX market cap and volume?

What is RPRX current Stock IQ?

Should I buy RPRX stock right now?

Is RPRX a Strong Buy right now?

What does a 'Strong Buy' rating mean for RPRX?

What does a 'Strong Sell' rating mean for RPRX?

What factors influence RPRX's Stock IQ?

Explore our RPRX Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored RPRX Stock Strategies
Effective Risk Management

FIND US ON

Receive our RPRX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

RPRX

Royalty Pharma plc

Set Alerts

Current Price

$39.72

-$0.49 | -1.22%

52W High

$41.7

MKT CAP

$22.93B

52W Low

$29.66

VOL

$2.42M

P/E Ratio

22.72

AVG VOL

$4.09M

RSI

52.20

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

RPRX Stock IQ

Login to unlock Royalty Pharma plc (RPRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

RPRX Rewards

Earnings are forecast to grow

RPRX Rewards

Pays a reliable dividend

RPRX Rewards

Upgraded on attractively valued

Linked to RPRX

Symbol

IQ

Close

Change

TEVA

4.43

32.35

-0.90%

RPRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

RPRX Street Sentiment

RPRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

RPRX Risk Level

RPRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

RPRX Performance Sentiment

Sentiments overview associated with RPRX events and the stock performance.

84%

0%

Positive

Negative

16 out of 19
events present

0 out of 19
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$40.21

Resistance
Price

$38.31

Current Price Range

$41.39

Show methods +

RPRX Latest Analysis

Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.

Tue Jan 13, 2026

$40.36 | +0.21%

Activity

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug. Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate TEV-408 while keeping global commercial control.

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference. – Strong Sephience™. (sepiapterin) launch continues with unaudited Q4 global revenue of – Unaudited 2025 total product and royalty revenue of approximately – 2026 product revenue guidance of – Strong cash position of approximately ) today provided an update on the Company'.s progress and its outlook for 2026. ".2025 was a highly successful year for PTC highlighted by the initial regulatory approvals of Seph

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

Potential

Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment . (RTTNews) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals a United States affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) have announced a funding agreement of up to $500 million to advance the clinical development of Tevas anti-IL-15 antibody candidate TEV-408 for vit

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development . (RTTNews) - Royalty Pharma plc (RPRX) and Teva Pharmaceuticals a United States affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) have entered into a funding agreement of up to $500 million to accelerate the clinical development of Tevas anti-IL-15 antibody TEV-408. IL-15 is a ke

Mon Jan 12, 2026

$40.28 | +0.27%

Activity

Royalty Pharma raises quarterly dividend by 6.8% to $0.235/share.

Fri Jan 9, 2026

$40.17 | -0.22%

Activity

Royalty Pharma Announces Dividend Increase. NEW YORK Jan. 09 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share reflecting a 6.8% increase in the companys quarterly dividend over the previous quarters dividend.

Fri Jan 9, 2026

$40.17 | -0.22%

Activity

Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics . (RTTNews) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics remaining royalty interest in Roches Evrysdi. The transaction includes an upfront payment of $240 million and up to $60 million in sales-based milestone payments.

Tue Dec 30, 2025

$38.99 | -0.23%

Activity

Royalty Pharma Acquires Remaining Royalty Interest in Roches Evrysdi for $240 Million and Potential Milestones. Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020

Mon Dec 29, 2025

$39.08 | -0.36%

Activity

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi.

Mon Dec 29, 2025

$39.08 | -0.36%

Activity

Discover RPRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of RPRX. We're here to help you make informed investment decisions today.

FIND US ON

Receive our RPRX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

RPRX Stock trends

RPRX Stock performance

RPRX Stock analysis

RPRX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing RPRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing RPRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

RPRX Stock Analysis & IQ Rating | Royalty Pharma plc

RPRX Stock IQ

RPRX Target Price

RPRX Risk Level

RPRX Analysts Opinion

RPRX Street Sentiment

RPRX Performance Sentiment

Technical Price Levels

Explore our RPRX Stock insights

Receive our RPRX Daily Alerts

RPRX Street Sentiment

RPRX Risk Level

Technical Price Levels

Discover RPRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of RPRX. We're here to help you make informed investment decisions today.

Receive our RPRX Daily Alerts

RPRX Alerts